IAM logo

Iambic Therapeutics Inc.

IAM
Healthcare|Biotechnology|US
$10.17
-1.47 (-12.63%)
Financing Filings (last 12 months)
3
Shelf registrations / offering prospectuses — latest Oct 15, 2026 (424B4). Possible dilution.

Upcoming Data Readouts (1)

Dec 2027
Est. completion
P1HER2 Mutation-Related Tumors
A Phase 1/1b Study of IAM1363 in HER2 Cancers
NCT06253871n=383

Recent Press Releases

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers
Oct 26, 2026 · Business Wire
Iambic Announces Pricing of Initial Public Offering
Oct 14, 2026 · Business Wire

SEC Filings (13)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 16, 20268-KMaterial eventDocumentIndex
Oct 15, 2026424B4Offering prospectusDocumentIndex
Oct 15, 2026S-8Employee stock planDocumentIndex
Oct 14, 2026EFFECTDocumentIndex
Oct 14, 2026CERTDocumentIndex
Oct 13, 20268-A12BDocumentIndex
Oct 8, 2026S-1/AIPO / offering registrationDocumentIndex
Sep 21, 2026S-1IPO / offering registrationDocumentIndex
Sep 9, 2026DDocumentIndex
Aug 28, 2026DRS/ADocumentIndex
Jul 24, 2026DRSDocumentIndex
Apr 8, 2026DDocumentIndex
Nov 21, 2025DDocumentIndex